Abstract
Cystic Fibrosis (CF) care has been revolutionised by the introduction of elexacaftor/tezacaftor/ivacaftor (ETI) therapy. Clinical trials have demonstrated positive effects of ETI on lung function, weight and quality of life, but little is known about how this treatment impacts the structural lung damage seen in established CF.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
